Literature DB >> 24942949

Tumor microenvironment and RIG-I signaling molecules in Epstein Barr virus-positive and -negative classical Hodgkin lymphoma of the elderly.

Tsugumi Satoh1, Ryuichi Wada, Nobuhisa Yajima, Tadaatsu Imaizumi, Soroku Yagihashi.   

Abstract

Classical Hodgkin lymphoma (CHL) is a B-cell neoplasm characterized by Hodgkin and Reed-Sternberg (HRS) cells. Its prevalence exhibits a bimodal pattern of peaking in young adults and the elderly. There is an association with Epstein-Barr virus (EBV) infection in about 50% of cases of CHL of the elderly, and the outcome of these patients is unfavorable. It is not well known how the latent infection of EBV is involved in the pathophysiology of CHL of the elderly. To address this issue, we examined the tumor microenvironment (TME) and the expression of molecules related to EBV infection in HRS cells in 10 EBV-positive CHL and 7 EBV-negative CHL patients older than 50 years. In EBV-positive CHL, we found an increased population of FOXP3(+) cells, while that of granzyme B(+) cells was reduced, compared with those in EBV-negative CHL. The expression of inhibitory chemokine CCL20 was increased in EBV-positive HRS cells compared with that in EBV-negative HRS cells. In addition, despite increased expression of a pattern recognition receptor, RIG-I, in intracellular innate immunity, there was no evidence of interferon regulatory factor 3 activation or interferon-ß induction in EBV-positive HRS cells in CHL of the elderly. The disease recurred frequently (50%) in EBV-positive CHL. The current study thus suggests the possibility that the latent infection of EBV alters the expression of chemokines and the innate immunity response in HRS cells and modulates TME to an immunosuppressive state, which may account for the unfavorable disease course in CHL of the elderly.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942949     DOI: 10.3960/jslrt.54.75

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  5 in total

Review 1.  Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus.

Authors:  Abhik Saha; Erle S Robertson
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

2.  Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.

Authors:  Mahdi Nohtani; Katerina Vrzalikova; Maha Ibrahim; Judith E Powell; Éanna Fennell; Susan Morgan; Richard Grundy; Keith McCarthy; Sarah Dewberry; Jan Bouchal; Katerina Bouchalova; Pamela Kearns; Paul G Murray
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

3.  Latent Membrane Protein 1 of Epstein-Barr Virus Promotes RIG-I Degradation Mediated by Proteasome Pathway.

Authors:  Chongfeng Xu; Lei Sun; Wenjun Liu; Ziyuan Duan
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

Review 4.  Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus.

Authors:  Leila Sawada; Antonio Carlos Rosário Vallinoto; Igor Brasil-Costa
Journal:  Biomolecules       Date:  2021-11-30

Review 5.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.